ArticleNeuropsychiatric disease and treatment2008
Potential cellular and regenerative approaches for the treatment of Parkinson's disease.
Article in Neuropsychiatric disease and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Cerebral Dopamine Neurotrophic Factor (CDNF) Acts as a Trophic Factor Promoting Neuritogenesis in the Dorsal Root Ganglia (DRG) Neurons Through Activation of the PI3K Signaling Pathway.Journal of neurochemistry · 2025Article
- Transcriptome profiling of five brain regions in a 6-hydroxydopamine rat model of Parkinson's disease.CNS neuroscience & therapeutics · 2021Article
- Novel Approaches Used to Examine and Control Neurogenesis in Parkinson's Disease.International journal of molecular sciences · 2021Review
- Advanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy.Advanced functional materials · 2020Article
- Stem cells: a promising candidate to treat neurological disorders.Neural regeneration research · 2018Review
- Induced pluripotent stem cells in rat models of Parkinson's disease: A systematic review and meta-analysis.Biomedical reports · 2018Article
- Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice.Acta neuropathologica communications · 2017Article
- Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.Neurochemical research · 2016Article
- Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.Cell proliferation · 2016Review
- Stem cell-based approach for the treatment of Parkinson's disease.Medical journal of the Islamic Republic of Iran · 2015Review
- Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.Parkinson's disease · 2015Review
- Intrabodies as neuroprotective therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Potential sources of stem cells as a regenerative therapy for Parkinson's disease.Stem cells and cloning : advances and applications · 2010Review
- Stereotactic implantation of deep brain stimulation electrodes: a review of technical systems, methods and emerging tools.Medical & biological engineering & computing · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease is most commonly treated with a range of pharmacotherapeutics, with the more recent introduction of surgical techniques including deep-brain stimulation. These have limited capabilities to improve symptoms of the disease in more advanced stages, thus new therapeutic strategies including the use of viral vectors and stem cells are in development. Providing a continuous supply of dopamine to the striatum in an attempt to improve the treatment of motor symptoms using enzymes in the dopamine synthesis and machinery is one approach. Alternatively, there are tools which may serve to both protect and encourage outgrowth of surviving neurons using growth factors or to directly replace lost innervation by transplantation of primary tissue or stem cell-derived dopaminergic neurons. We summarize some of the potential therapeutic approaches and also consider the recent EU directives on practical aspects of handling viral vectors, cells and tissues, and in the running of clinical trials in Europe which impact on their development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.